Back to top
more

ADMA Biologics (ADMA)

(Real Time Quote from BATS)

$10.46 USD

10.46
1,800,807

-0.01 (-0.10%)

Updated Jun 10, 2024 03:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised

by Zacks Equity Research

Intra-Cellular (ITCI) reports better-than-expected second-quarter results. Caplyta sales continue to drive growth. The company raises its financial outlook for full-year Caplyta sales.

Acadia (ACAD) Q2 Earnings & Revenues Beat Estimates, '23 View Up

by Zacks Equity Research

Acadia (ACAD) reports better-than-expected second-quarter 2023 results, raising its financial guidance for the year. The company also provides updates on its pipeline.

Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated

by Zacks Equity Research

Pacira (PCRX) announces weaker-than-expected second-quarter 2023 results. The company updates its 2023 financial guidance.

Apellis (APLS) Q2 Earnings Top, Syfovre Sales Boost Revenues

by Zacks Equity Research

Apellis (APLS) reports better-than-expected second-quarter 2023 results. However, the stock falls 20% due to ambiguity surrounding Syfovre's safety profile.

ADMA Biologics (ADMA) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

On ADMA Biologics' (ADMA) Q2 earnings call, investors will likely focus on the sales performance of its immune deficiency disorder drugs.

Adma Biologics (ADMA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Adma Biologics (ADMA) closed the most recent trading day at $3.76, moving +0.53% from the previous trading session.

Adma Biologics (ADMA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Adma Biologics (ADMA) closed at $3.49, marking a +0.58% move from the previous day.

New Strong Buy Stocks for July 7th

by Zacks Equity Research

ADMA, APOG, KIND, JBL and OII have been added to the Zacks Rank #1 (Strong Buy) List on July 7, 2023.

Vertex (VRTX) Gets Nod in EU for Orkambi Expanded Indication

by Zacks Equity Research

Vertex's (VRTX) Orkambi gets approval from the European Commission in the EU for the treatment of cystic fibrosis in patients (aged 1 to <2 years) who have two copies of the F508del mutation.

CRISPR (CRSP) Shares Rise 24% in the Last Quarter: Here's Why

by Zacks Equity Research

Shares of CRISPR (CRSP) surge 24% in the last quarter after the company, along with Vertex, provides positive regulatory updates on exa-cel BLAs in SCD and TDT treatment.

Alnylam (ALNY) Announces FDA Committee Onpattro sNDA Review Date

by Zacks Equity Research

Alnylam (ALNY) reports that the FDA has set Sep 13, 2023, as the day for the meeting of the Advisory Committee to review its sNDA application for patisiran in treating the cardiomyopathy of ATTR amyloidosis.

Kintara (KTRA) Rises 41% on $2M Grant for Breast Cancer Therapy

by Zacks Equity Research

Kintara (KTRA) receives a $2 million grant from the National Institutes of Health to develop its breast cancer treatment candidate, REM-001. The stock surges 41%.

Liquidia (LQDA) Up on Deal With Pharmosa to Co-Develop PH Drug

by Zacks Equity Research

Liquidia (LQDA) signs an exclusive licensing agreement with Pharmosa to jointly develop and commercialize PAH and PH-ILD treatment candidate, L606, in North America. Shares of the company rise 11%.

Aeglea (AGLE) Soars 329% on Acquiring Spyre Therapeutics

by Zacks Equity Research

Aeglea's (AGLE) shares surge as it acquires Spyre Therapeutics, a private company that focuses on developing antibody therapeutics for inflammatory bowel disease.

uniQure (QURE) Falls on Mixed Huntington's Disease Study Results

by Zacks Equity Research

uniQure (QURE) stock declines after the company announces mixed results from its biomarkers analysis in the early-to-mid-stage study of AMT-130 in Huntington's disease.

Amgen's (AMGN) Blincyto sBLA Gets FDA Nod in Treating Leukemia

by Zacks Equity Research

Amgen (AMGN) announces full approval of its sBLA for Blincyto as an immune-oncology therapy for treating adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia.

Alderya (ALDX) Stock Declines on Getting CRL for PVRL Candidate

by Zacks Equity Research

Alderya's (ALDX) shares decline on receiving a complete response letter for an investigational candidate, ADX-2191, treating primary vitreoretinal lymphoma.

Denali (DNLI) Provides Update on Hunter Syndrome Study

by Zacks Equity Research

Denali's (DNLI) early-to-mid-stage study of DNL310 shows a robust reduction in neurofilament light levels for patients with MPS II (Hunter syndrome).

Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug

by Zacks Equity Research

Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.

Merck's (MRK) Gastric Cancer Study Fails to Meet a Primary Goal

by Zacks Equity Research

Merck's (MRK) late-stage study evaluating Keytruda in advanced gastric cancer fails to meet one of the primary endpoints.

Reata (RETA) Announces FDA's Acceptance of Skyclarys PAS

by Zacks Equity Research

Reata (RETA) gets FDA acceptance for the filing of new drug application supplement approval for Skyclarys' release.

GSK Announces Extension of FDA Review for Rare Blood Therapy

by Zacks Equity Research

GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision is now expected on Sep 16, 2023.

Mersana (MRSN) Down on Partial Ovarian Cancer Study Hold

by Zacks Equity Research

Mersana's (MRSN) shares decline on partial clinical hold by the FDA on UP-NEXT and UPGRADE-A studies evaluating upifitamab rilsodotin to treat platinum-sensitive ovarian cancer.

Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study

by Zacks Equity Research

Aldeyra (ALDX) soars on meeting primary and secondary endpoints in the late-stage study of reproxalap for patients with allergic conjunctivitis.

Blue Water (BWV) Up on Acquisition of 6 FDA-Approved Drugs

by Zacks Equity Research

Blue Water (BWV) soars 62% after declaring its deal to purchase six FDA-approved products for $8.5 million. The agreement will help expand the company's portfolio into cardiology and pain management.